Since ponatinib targets several tyrosine kinases and only FGFR1-activated PI3K/AKT/mTOR and JAK/STAT3 signaling pathways have been investigated in this paper, it is highly likely that the inhibition of other targets also contributed to ponatinib-induced anti-tumor effect in NB. The gene discussed is FGFR1; the disease is neoplasm.